Seagen and lava therapeutics announce exclusive worldwide license agreement to advance lava-1223, a preclinical gamma delta bispecific t cell engager for egfr-expressing solid tumors

Bothell, wash. & utrecht, netherlands & philadelphia--(business wire)--seagen inc. (nasdaq: sgen), a world leader and pioneer in antibody-drug conjugate (adc) therapies, and lava therapeutics n.v. (nasdaq: lvtx), a clinical-stage immuno-oncology company focused on developing its proprietary gammabody™ platform of bispecific gamma delta t cell engagers, today announced an exclusive license agreement in which seagen will work to develop, manufacture and commercialize lava-1223. lava-1223 is an ad
SGEN Ratings Summary
SGEN Quant Ranking